Chronic Vision Loss: Glaucoma, Cataract, AMD & Retinopathy
Map the lost vision to the disease, then protect what's left
Patterns of chronic vision loss
Painless and gradual. Four conditions cause most chronic vision loss in adults, and the pattern of loss points to the culprit. Glaucoma erodes the peripheral field while central acuity survives until late; macular degeneration destroys the central vision needed for reading and faces; cataract blurs the whole image and adds glare and halos; diabetic retinopathy blurs central vision through macular edema or causes sudden floaters and loss from vitreous hemorrhage. Cataract is the leading cause of blindness worldwide but is reversible, glaucoma is the leading cause of irreversible blindness worldwide, AMD is the leading cause of irreversible vision loss in older adults in high-income countries, and diabetic retinopathy is the leading cause of new blindness in working-age adults.
| Feature | Open-angle glaucoma | Cataract | AMD | Diabetic retinopathy |
|---|---|---|---|---|
| Vision lost | Peripheral field first | Global blur, glare, halos | Central vision | Central blur (edema) or sudden floaters (hemorrhage) |
| Key finding | Cup-to-disc ratio >0.5 | Diminished red reflex | Drusen; neovascular membrane in wet form | Microaneurysms, hemorrhages, exudates, new vessels |
| Key treatment | Prostaglandin analog drops | Surgery with lens implant | AREDS2 (dry); anti-VEGF (wet) | Anti-VEGF, panretinal photocoagulation |
Primary open-angle glaucoma
Mechanism. Glaucoma is a progressive optic neuropathy: retinal ganglion cell axons die and the optic disc cups. Aqueous humor made by the ciliary body normally drains through the trabecular meshwork into Schlemm canal, with a smaller uveoscleral route. In open-angle disease the angle looks normal on gonioscopy, but trabecular outflow resistance rises. An IOP above 21 mmHg is the main modifiable risk factor, yet damage can occur at normal pressures (normal-tension glaucoma).
Findings. The disease is silent until advanced. Arcuate and nasal-step field defects coalesce into tunnel vision while central acuity is preserved until late. The disc shows a cup-to-disc ratio >0.5, asymmetry >0.2 between eyes, notching of the neuroretinal rim or a splinter hemorrhage at the disc margin. Evaluation includes tonometry, gonioscopy, automated perimetry, optical coherence tomography (OCT) of the nerve fiber layer, and pachymetry, because a thin central cornea both underestimates IOP and independently raises risk.
Risk factors and screening. Age over 60, Black race (more common, earlier and more aggressive disease), first-degree family history, myopia, elevated IOP, thin cornea and chronic corticosteroid use. Glaucoma is the leading cause of blindness among Black Americans. Because early disease causes no symptoms, adults should have a baseline comprehensive eye exam by about age 40, sooner and more often if high risk.
| Class | Examples | Mechanism | Adverse effects and cautions |
|---|---|---|---|
| Prostaglandin analogs (first line) | Latanoprost, bimatoprost, travoprost | ↑ Uveoscleral outflow | Permanent brown iris darkening, eyelash growth, periocular pigmentation, periorbital fat atrophy, hyperemia |
| β-blockers | Timolol | ↓ Aqueous production | Bradycardia, heart block, bronchospasm; avoid in asthma, COPD, AV block |
| α2 agonists | Brimonidine | ↓ Production, ↑ uveoscleral outflow | Allergic conjunctivitis, fatigue, dry mouth; contraindicated in children under 2 years (CNS depression, apnea); use caution in young children |
| Carbonic anhydrase inhibitors | Dorzolamide, brinzolamide; oral acetazolamide | ↓ Aqueous production | Oral: paresthesias, hypokalemia, normal anion gap metabolic acidosis, kidney stones; sulfonamide caution |
| Rho kinase inhibitor | Netarsudil | ↑ Trabecular outflow | Conjunctival hyperemia |
| Cholinergic agonists | Pilocarpine | ↑ Trabecular outflow via ciliary muscle contraction | Miosis, brow ache, dim night vision |
Topical timolol drains through the nasolacrimal duct into the circulation. Pressing on the medial canthus (punctal occlusion) for a minute after each drop reduces systemic effects.
Beyond drops. Selective laser trabeculoplasty is an effective first-line alternative to medication. When IOP remains uncontrolled, trabeculectomy or a tube shunt creates a new drainage route.
Acute angle-closure glaucoma is a different disease: a painful red eye, halos and a fixed mid-dilated pupil demand emergency pressure lowering, and mydriatics can precipitate it.
Cataract
Presentation. Opacification of the lens produces gradual, painless blur, glare and halos (classically with oncoming headlights at night), faded colors, reduced contrast and frequent changes in glasses prescription. Nuclear sclerosis can shift refraction toward myopia, briefly improving near vision ("second sight"). The red reflex is diminished or shows dark spots, and the slit lamp confirms the opacity.
Risk factors. Age dominates. Others are smoking, ultraviolet exposure, alcohol, diabetes (aldose reductase converts glucose to osmotically active sorbitol in the lens), corticosteroids by any route (characteristically posterior subcapsular cataract), trauma and radiation.
Treatment. No medication reverses a cataract. Phacoemulsification with an intraocular lens implant is indicated when blur interferes with daily activities such as driving or reading, not at a fixed acuity threshold. Months to years later, the retained posterior capsule may cloud ("secondary cataract"); Nd:YAG laser capsulotomy clears it in minutes.
Age-related macular degeneration
Dry (atrophic) AMD. About 85–90% of cases. Yellow drusen accumulate between the retinal pigment epithelium (RPE) and Bruch membrane, with pigment clumping and eventually geographic atrophy, causing gradual central blur over years while peripheral vision is spared. Risk factors are age, smoking (the most important modifiable factor), family history (complement factor H variants) and White race.
AREDS2. For intermediate AMD (large drusen) or advanced AMD in one eye, high-dose vitamins C and E, zinc, copper, lutein and zeaxanthin reduce progression to advanced AMD by about 25% over 5 years; they do not help early AMD. The original AREDS formula used β-carotene, which increased lung cancer risk in smokers, so AREDS2 replaced it with lutein and zeaxanthin. Intravitreal complement inhibitors can modestly slow geographic atrophy.
Wet (neovascular) AMD. A minority of cases but most severe vision loss. Choroidal new vessels break through Bruch membrane and leak fluid or blood beneath the macula, causing central scotoma and metamorphopsia over days to weeks: straight lines look wavy on an Amsler grid. OCT shows the fluid and fluorescein angiography shows the leaking membrane. Repeated intravitreal anti-VEGF injections (ranibizumab, aflibercept, bevacizumab) started urgently preserve and often improve vision; untreated lesions end in a disciform scar.
Patients with intermediate AMD should check each eye with an Amsler grid regularly; new distortion warrants ophthalmology evaluation within days.
Diabetic retinopathy
Pathogenesis. Chronic hyperglycemia causes pericyte loss and capillary basement-membrane thickening, leading to microaneurysms, leakage and capillary closure. Ischemic retina releases VEGF, which drives neovascularization.
Screening. Dilated eye exams (or validated retinal photography) begin at diagnosis in type 2 diabetes, because disease may have been present for years, and within 5 years of onset in type 1. Exams are then yearly, or every 1–2 years when no retinopathy is found and control is good. Women with preexisting diabetes need an exam before conception or in the first trimester, then each trimester and up to 1 year postpartum, since pregnancy can accelerate retinopathy; gestational diabetes does not require retinal screening.
| Stage | Findings | Management |
|---|---|---|
| Nonproliferative (NPDR) | Microaneurysms (earliest), dot-blot hemorrhages, hard exudates, cotton-wool spots; venous beading and IRMA when severe | Glucose, BP and lipid control; closer follow-up |
| Proliferative (PDR) | Neovascularization of the disc or elsewhere; vitreous hemorrhage, traction detachment, iris rubeosis | Panretinal photocoagulation or anti-VEGF; vitrectomy for nonclearing hemorrhage or traction |
| Macular edema (any stage) | Retinal thickening and hard exudates near the fovea | Center-involving with vision loss: intravitreal anti-VEGF |
Nonproliferative disease. Hard exudates are yellow lipid deposits, often in rings; cotton-wool spots are nerve fiber layer microinfarcts; venous beading and intraretinal microvascular abnormalities (IRMA) signal severe ischemia and high risk of progression.
Proliferative disease. Fragile new vessels bleed into the vitreous, producing sudden painless floaters or vision loss, and fibrovascular tissue contracts to cause traction retinal detachment. New vessels on the iris and angle cause neovascular glaucoma. Panretinal photocoagulation ablates ischemic peripheral retina to cut the VEGF drive, at some cost to peripheral and night vision; intravitreal anti-VEGF is an alternative. Vitrectomy clears nonresolving hemorrhage and relieves traction threatening the macula.
Macular edema. Leakage near the fovea is the most common cause of vision loss in diabetic retinopathy and can occur at any stage. Center-involving edema with reduced acuity is treated first with intravitreal anti-VEGF; focal laser and intravitreal steroids are alternatives. Glucose, blood pressure and lipid control slow every stage, although rapid intensification of glucose control can transiently worsen retinopathy.
Hypertensive retinopathy
Chronic changes. Long-standing hypertension narrows arterioles and thickens their walls (arteriolosclerosis), so the light reflex widens into "copper wiring" and later "silver wiring." At crossings, thickened arterioles compress venules (arteriovenous nicking). More severe disease adds flame-shaped hemorrhages, cotton-wool spots and hard exudates, sometimes radiating around the fovea as a macular star. These findings track stroke and cardiovascular risk, and treatment is blood pressure control.
Flame-shaped hemorrhages lie in the superficial nerve fiber layer (hypertension, retinal vein occlusion); dot-blot hemorrhages lie deeper in the retina (diabetes).
Malignant hypertension. Optic disc swelling with severe hypertension (typically >180/120 mmHg) is end-organ damage and defines a hypertensive emergency.
- Admit to the ICUStart a titratable IV agent such as nicardipine, clevidipine or labetalol with arterial line monitoring.
- First hourLower mean arterial pressure by no more than 25%; abrupt normalization risks cerebral and retinal hypoperfusion.
- Next 2–6 hoursIf stable, bring BP toward 160/100–110 mmHg.
- Following 24–48 hoursCautiously normalize BP and transition to oral therapy.